- Home
- TSI vs NLSP Comparison
TSI vs NLSP Comparison
Compare TSI & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSI
- NLSP
- Stock Information
- Founded
- TSI 1987
- NLSP 2015
- Country
- TSI United States
- NLSP Switzerland
- Employees
- TSI N/A
- NLSP N/A
- Industry
- TSI Investment Managers
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- TSI Finance
- NLSP Health Care
- Exchange
- TSI Nasdaq
- NLSP Nasdaq
- Market Cap
- TSI 236.5M
- NLSP 12.4M
- IPO Year
- TSI N/A
- NLSP 2021
- Fundamental
- Price
- TSI $4.99
- NLSP $2.15
- Analyst Decision
- TSI
- NLSP
- Analyst Count
- TSI 0
- NLSP 0
- Target Price
- TSI N/A
- NLSP N/A
- AVG Volume (30 Days)
- TSI 106.8K
- NLSP 193.3K
- Earning Date
- TSI 01-01-0001
- NLSP 10-17-2025
- Dividend Yield
- TSI 7.46%
- NLSP N/A
- EPS Growth
- TSI N/A
- NLSP N/A
- EPS
- TSI N/A
- NLSP N/A
- Revenue
- TSI N/A
- NLSP N/A
- Revenue This Year
- TSI N/A
- NLSP N/A
- Revenue Next Year
- TSI N/A
- NLSP N/A
- P/E Ratio
- TSI N/A
- NLSP N/A
- Revenue Growth
- TSI N/A
- NLSP N/A
- 52 Week Low
- TSI $4.48
- NLSP $1.30
- 52 Week High
- TSI $4.87
- NLSP $6.97
- Technical
- Relative Strength Index (RSI)
- TSI 64.26
- NLSP 48.82
- Support Level
- TSI $4.96
- NLSP $1.88
- Resistance Level
- TSI $5.00
- NLSP $2.02
- Average True Range (ATR)
- TSI 0.03
- NLSP 0.14
- MACD
- TSI 0.00
- NLSP -0.02
- Stochastic Oscillator
- TSI 86.00
- NLSP 33.33
About TSI TCW Strategic Income Fund Inc.
Tcw Strategic Income Fund Inc operates as a closed-end management investment company. Its investment objective is to seek a total return comprised of current income and capital appreciation by investing in a wide range of securities. The company invests in a range of industries, such as airlines, banks, beverages, biotechnology, chemicals, computers, diversified financial services, entertainment and others.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.